D. E. Shaw & Co., Inc. Mannkind Corp Transaction History

D. E. Shaw & Co., Inc.

$156 Billion
Q3 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Mannkind Corp stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 856,946 shares of MNKD stock, worth $4.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

856,946

Previous 2,522,678 66.03%

Holding current value

$4.34 Million

Previous $9.43 Million 51.23%

% of portfolio

0.0%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$3.42 - $5.74 $5.7 Million - $9.56 Million	-1,665,732 Reduced 66.03%	856,946 $4.6 Million
Q2 2025 Aug 14, 2025	SELL	$3.71 - $5.04 $4.88 Million - $6.63 Million	-1,314,956 Reduced 34.26%	2,522,678 $9.43 Million
Q1 2025 May 15, 2025	SELL	$4.92 - $6.6 $2.12 Million - $2.85 Million	-431,429 Reduced 10.11%	3,837,634 $19.3 Million
Q4 2024 Feb 14, 2025	BUY	$5.93 - $7.44 $4.73 Million - $5.94 Million	798,469 Added 23.01%	4,269,063 $27.5 Million
Q3 2024 Nov 14, 2024	BUY	$5.01 - $6.7 $2.93 Million - $3.92 Million	585,806 Added 20.31%	3,470,594 $21.8 Million

Q2 2024 Aug 14, 2024	BUY	$4.05 - $5.43 $743,308 - $996,584	183,533 Added 6.79%	2,884,788 $15.1 Million
Q1 2024 May 15, 2024	SELL	$3.25 - $5.27 $932,002 - $1.51 Million	-286,770 Reduced 9.6%	2,701,255 $12.2 Million
Q4 2023 Feb 14, 2024	SELL	$3.34 - $4.29 $4.07 Million - $5.23 Million	-1,219,366 Reduced 28.98%	2,988,025 $10.9 Million
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.45 $883,057 - $1.23 Million	225,846 Added 5.67%	4,207,391 $17.4 Million
Q2 2023 Aug 14, 2023	SELL	$3.72 - $4.79 $6.8 Million - $8.76 Million	-1,828,508 Reduced 31.47%	3,981,545 $16.2 Million
Q1 2023 May 15, 2023	BUY	$3.95 - $5.63 $819,064 - $1.17 Million	207,358 Added 3.7%	5,810,053 $23.8 Million
Q4 2022 Feb 14, 2023	BUY	$3.02 - $5.37 $6.42 Million - $11.4 Million	2,124,534 Added 61.08%	5,602,695 $29.5 Million
Q3 2022 Nov 14, 2022	BUY	$2.99 - $4.35 $689,093 - $1 Million	230,466 Added 7.1%	3,478,161 $10.7 Million
Q2 2022 Aug 15, 2022	BUY	$2.67 - $4.77 $5.33 Million - $9.52 Million	1,994,946 Added 159.25%	3,247,695 $12.4 Million
Q1 2022 May 16, 2022	BUY	$2.62 - $4.45 $3.28 Million - $5.57 Million	1,252,749 New	1,252,749 $4.61 Million
Q3 2020 Nov 16, 2020	SELL	$1.56 - $2.08 $37,235 - $49,647	-23,869 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$0.94 - $2.21 $632,845 - $1.49 Million	-673,240 Reduced 96.58%	23,869 $42,000
Q1 2020 May 15, 2020	SELL	$0.84 - $1.76 $390,654 - $818,514	-465,065 Reduced 40.02%	697,109 $718,000
Q4 2019 Feb 14, 2020	SELL	$1.14 - $1.49 $104,428 - $136,489	-91,604 Reduced 7.31%	1,162,174 $1.5 Million
Q3 2019 Nov 14, 2019	SELL	$1.04 - $1.44 $839,190 - $1.16 Million	-806,914 Reduced 39.16%	1,253,778 $1.57 Million
Q2 2019 Aug 14, 2019	SELL	$1.09 - $1.88 $1.12 Million - $1.92 Million	-1,023,189 Reduced 33.18%	2,060,692 $2.37 Million
Q1 2019 May 15, 2019	BUY	$1.14 - $2.25 $2.13 Million - $4.21 Million	1,869,543 Added 153.96%	3,083,881 $6.08 Million
Q4 2018 Feb 14, 2019	SELL	$1.02 - $2.05 $709,774 - $1.43 Million	-695,857 Reduced 36.43%	1,214,338 $1.29 Million
Q3 2018 Nov 14, 2018	SELL	$1.01 - $2.19 $2.06 Million - $4.47 Million	-2,040,598 Reduced 51.65%	1,910,195 $3.5 Million
Q2 2018 Aug 14, 2018	SELL	$1.59 - $2.38 $1.65 Million - $2.47 Million	-1,037,412 Reduced 20.8%	3,950,793 $7.51 Million
Q1 2018 May 15, 2018	BUY	$2.28 - $3.8 $2.2 Million - $3.66 Million	963,649 Added 23.94%	4,988,205 $11.4 Million
Q4 2017 Feb 14, 2018	BUY	$2.28 - $6.71 $6.38 Million - $18.8 Million	2,796,577 Added 227.74%	4,024,556 $9.34 Million
Q3 2017 Nov 14, 2017	BUY	$1.15 - $2.29 $1.41 Million - $2.81 Million	1,227,979	1,227,979 $2.67 Million

Others Institutions Holding MNKD

# of Institutions

255

Shares Held

165M

Call Options Held

2.76M

Put Options Held

689K

View Full List

About MANNKIND CORP

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.3B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

More about MNKD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account